American health care reform: An international perspective
Author
Abstract
Suggested Citation
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- F. M. Scherer, 1993. "Pricing, Profits, and Technological Progress in the Pharmaceutical Industry," Journal of Economic Perspectives, American Economic Association, vol. 7(3), pages 97-115, Summer.
- Hoffman, Alan N. & Nurick, Aaron J., 1991. "Choosing health care coverage: Considerations of physician motivation," Business Horizons, Elsevier, vol. 34(3), pages 67-71.
- Minifie, J. R. & Davis, R. A., 1987. "Innovative programs for the long-term survival of the American hospital industry," Engineering Costs and Production Economics, Elsevier, vol. 12(1-4), pages 327-333, July.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Edgardo Barandiarán & Ricardo Paredes, 2002. "Protección de la competencia en Chile: El Estado vs Laboratorios Chile y Recalcine (1992/93)," Working Papers wp191, University of Chile, Department of Economics.
- Roger Feldman & Félix Lobo, 2013. "Competition in prescription drug markets: the roles of trademarks, advertising, and generic names," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(4), pages 667-675, August.
- Brekke, Kurt R. & Konigbauer, Ingrid & Straume, Odd Rune, 2007.
"Reference pricing of pharmaceuticals,"
Journal of Health Economics, Elsevier, vol. 26(3), pages 613-642, May.
- Brekke, Kurt R & Königbauer, Ingrid & Straume, Odd Rune, 2005. "Reference Pricing of Pharmaceuticals," Working Papers in Economics 19/05, University of Bergen, Department of Economics.
- Kurt R. Brekke & Ingrid Königbauer & Odd Rune Straume, 2006. "Reference Pricing of Pharmaceuticals," CESifo Working Paper Series 1825, CESifo.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Kaiser, Ulrich & Mendez, Susan J. & Rønde, Thomas & Ullrich, Hannes, 2014.
"Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark,"
Journal of Health Economics, Elsevier, vol. 36(C), pages 174-187.
- Kaiser, Ulrich & Mendez, Susan J. & Rønde, Thomas, 2010. "Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark," ZEW Discussion Papers 10-062, ZEW - Leibniz Centre for European Economic Research.
- Ulrich Kaiser & Susan J. Mendez & Thomas Rønde, 2010. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," CIE Discussion Papers 2010-01, University of Copenhagen. Department of Economics. Centre for Industrial Economics.
- Ulrich Kaiser & Susan J. Méndez & Thomas Rønde & Hannes Ullrich, 2013. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," Working Papers 330, University of Zurich, Department of Business Administration (IBW).
- Kaiser, Ulrich & Méndez, Susan J. & Rønde, Thomas & Ullrich, Hannes, 2013. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," IZA Discussion Papers 7248, Institute of Labor Economics (IZA).
- Kaiser, Ulrich & Méndez, Susan & Rønde, Thomas & Ullrich, Hannes, 2013. "Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark," VfS Annual Conference 2013 (Duesseldorf): Competition Policy and Regulation in a Global Economic Order 79937, Verein für Socialpolitik / German Economic Association.
- Aysegul Timur & Gabriel Picone & Jeffrey DeSimone, 2011.
"Has the European union achieved a single pharmaceutical market?,"
International Journal of Health Economics and Management, Springer, vol. 11(4), pages 223-244, December.
- Aysegul Timur & Gabriel Picone & Jeffrey S. DeSimone, 2010. "Has the European Union Achieved a Single Pharmaceutical Market?," NBER Working Papers 16261, National Bureau of Economic Research, Inc.
- Tapon, Francis & Cadsby, Charles Bram, 1996. "The optimal organization of research: evidence from eight case studies of pharmaceutical firms," Journal of Economic Behavior & Organization, Elsevier, vol. 31(3), pages 381-399, December.
- Unsorg Maximiliane, 2022.
"Reference pricing systems on the pharmaceutical market,"
German Economic Review, De Gruyter, vol. 23(3), pages 403-421, August.
- Unsorg, Maximiliane, 2018. "Reference Pricing Systems on the Pharmaceutical Market," VfS Annual Conference 2018 (Freiburg, Breisgau): Digital Economy 181533, Verein für Socialpolitik / German Economic Association.
- Unsorg, Maximiliane, 2018. "Reference pricing systems on the pharmaceutical market," University of Tübingen Working Papers in Business and Economics 115, University of Tuebingen, Faculty of Economics and Social Sciences, School of Business and Economics.
- Inderst, Roman, 2002. "Why competition may drive up prices," Journal of Economic Behavior & Organization, Elsevier, vol. 47(4), pages 451-462, April.
- Kyle, Margaret K. & Ridley, David B. & Zhang, Su, 2017.
"Strategic interaction among governments in the provision of a global public good,"
Journal of Public Economics, Elsevier, vol. 156(C), pages 185-199.
- Margaret Kyle & David Ridley & Su Zhang, 2017. "Strategic interaction among governments in the provision of a global public good," Post-Print hal-01952672, HAL.
- Margaret Kyle & David Ridley & Su Zhang, 2017. "Strategic interaction among governments in the provision of a global public good," Post-Print hal-01952712, HAL.
- Kyle, Margaret & Ridley, David & Zhang, Su, 2017. "Strategic Interaction Among Governments in the Provision of a Global Public Good," CEPR Discussion Papers 12419, C.E.P.R. Discussion Papers.
- Chatterjee, Chirantan & Gupta, Samarth, 2024. "Public entry and private prices: New evidence from Indian pharmaceutical markets," Journal of Economic Behavior & Organization, Elsevier, vol. 219(C), pages 473-489.
- Gehl Sampath, Padmashree, 2003. "Designing National Regimes that Promote Public Health Objectives," UNU-INTECH Discussion Paper Series 2003-08, United Nations University - INTECH.
- Giaccotto, Carmelo & Santerre, Rexford E & Vernon, John A, 2005. "Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry," Journal of Law and Economics, University of Chicago Press, vol. 48(1), pages 195-214, April.
- Georges Siotis & Carmine Ornaghi & Micael Castanheira, 2023.
"Evolving market boundaries and competition policy enforcement in the pharmaceutical industry,"
European Journal of Law and Economics, Springer, vol. 55(2), pages 313-348, April.
- Micael Castanheira De Moura & Georges Siotis & Carmine Ornaghi, 2023. "Evolving Market Boundaries and Competition Policy Enforcement in the Pharmaceutical Industry," ULB Institutional Repository 2013/353440, ULB -- Universite Libre de Bruxelles.
- Sarmah, Archita & De Giovanni, Domenico & De Giovanni, Pietro, 2020. "Compulsory licenses in the pharmaceutical industry: Pricing and R&D strategies," European Journal of Operational Research, Elsevier, vol. 282(3), pages 1053-1069.
- Ferrara, Ida & Kong, Ying, 2008. "Can health insurance coverage explain the generic competition paradox?," Economics Letters, Elsevier, vol. 101(1), pages 48-52, October.
- Whaley, Christopher M. & Brown, Timothy T., 2018. "Firm responses to targeted consumer incentives: Evidence from reference pricing for surgical services," Journal of Health Economics, Elsevier, vol. 61(C), pages 111-133.
- Nabin Munirul Haque & Mohan Vijay & Nicholas Aaron & Sgro Pasquale M., 2012. "Therapeutic Equivalence and the Generic Competition Paradox," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 12(1), pages 1-26, November.
- Bhattacharya, Jayanta & Vogt, William B, 2003. "A Simple Model of Pharmaceutical Price Dynamics," Journal of Law and Economics, University of Chicago Press, vol. 46(2), pages 599-626, October.
- Kane, Nancy M., 1997. "Pharmaceutical cost containment and innovation in the United States," Health Policy, Elsevier, vol. 41(Supplemen), pages 71-89, September.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:proeco:v:46-47:y:1996:i:1:p:497-509. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/locate/ijpe .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.